Ugochukwu Benjamin C.
- Country
- Germany
- Department
- Clinical Unit
Research Overview
- Evaluation of Pharmacokinetics, Safety, and Tolerability of Obefazimod in Patients with Renal Impairment and Normal Renal Function with Ulcerative Colitis
- Evaluation of Plasma Pharmacokinetics of Leniolisib in Subjects with Impaired Hepatic Function and Normal Hepatic Function in Activated Phosphoinositide 3-Kinase Delta Syndrome
- Pharmacokinetics of BI 456906 in Subjects with Varying Degrees of Renal Impairment and Healthy Controls
Data & Insights
Has run more than one trial at 1 of 6 partner sites.
Specializations
Renal Function Studies
The investigator specializes in studying the impact of renal impairment on drug pharmacokinetics, with particular focus on patients with varying degrees of kidney dysfunction.
- Mild to severe renal impairment assessment
- Drug metabolism in kidney dysfunction
- Comparative analysis with healthy subjects
Special attention is given to evaluating novel therapeutic compounds in patients with compromised kidney function.
Hepatic Studies
Expertise in investigating the effects of hepatic impairment on drug pharmacokinetics, including studies of innovative treatments for liver-related conditions.
- Liver function impact on drug metabolism
- Complement factor inhibition studies
- Hepatic function biomarkers
The research encompasses various degrees of liver dysfunction and their influence on drug processing.
Therapeutic Applications
Investigation of treatments for various conditions including autoimmune diseases and inflammatory disorders.
- Systemic and cutaneous lupus erythematosus
- Ulcerative colitis management
- Acute ischemic stroke interventions
Focus on developing therapeutic approaches for complex medical conditions requiring specialized treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.